. Splice targeting morpholino was designed against intron 5 -exon 6 within the dnm2a gene. Efficacy of the splice site targeting morpholino in I5E6dnm2a-MO injected embryos was verified using RT-PCR. Embryos were injected with a scrambled control morpholino (STD-MO; 0.32 pmol/embryo) and I5E6dnm2a-MO (0.32 pmol/embryo). Black arrow indicate the alternative splice product induced by I5E6dnm2a-MO injection. β-actin is the internal control. Supplementary Fig. 4 . Observed dose-dependent after testing MO at range of concentrations from 0.16 pmol/embryo to 0,96 pmol/embryo. 0.64 pmol/embryo is the chosen concentration for ATGdnm2a-MO (n = 736 embryos in 5 independent experiments), and 0.32 pmol/embryo is the chosen concentration for I5E6dnm2a-MO (n = 712 embryos in 5 independent experiments). Graph shows the percentage of embryos divided into classes according to morphology. Supplementary Fig. 5 . Western blot shows reduced Dnm2a (90kD) expression levels in ATGdnm2a-MO and I5E6dnm2a-MO-injected embryos. Actin (41kD) and BIN1 (70kD) are internal controls. Supplementary Fig. 6 . (A) Low doses (0.10 pmol/embryo) of ATGdnm2a-MO and I5E6dnm2a-MO were co-injected in the same embryos, compared with the injection of 0.10 pmol/embryo of STD-MO. (B) When combined, the morpholinos cause severe morphological alterations even at doses that were negligible on their own, confirming their targeting specificity.
